S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Will This Be the Worst U.S. Crisis Ever? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Will This Be the Worst U.S. Crisis Ever? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Will This Be the Worst U.S. Crisis Ever? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Will This Be the Worst U.S. Crisis Ever? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Will This Be the Worst U.S. Crisis Ever? (Ad)
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:ATRA

Atara Biotherapeutics - ATRA Earnings Date, Estimates & Call Transcripts

$4.69
+1.06 (+29.20%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.69
$4.92
50-Day Range
$2.85
$8.73
52-Week Range
$2.83
$20.04
Volume
14.54 million shs
Average Volume
1.50 million shs
Market Capitalization
$438.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.71

Earnings Summary

Upcoming
Earnings Date
Nov. 3Estimated
Actual EPS
(May. 5)
-$0.87 Beat By $0.11
Consensus EPS
(May. 5)
-$0.98
Last Year's Q2 EPS
(5/3/2021)
-$0.86
Skip Charts & View Estimated and Actual Earnings Data

ATRA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATRA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Atara Biotherapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.73)($0.73)($0.73)
Q2 20221($0.77)($0.77)($0.77)
Q3 20221($0.78)($0.78)($0.78)
Q4 20221($0.75)($0.75)($0.75)
FY 20224($3.03)($3.03)($3.03)

ATRA Earnings Date and Information

Atara Biotherapeutics last issued its earnings data on May 5th, 2022. The biotechnology company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.98) by $0.11. The business earned $7.31 million during the quarter, compared to the consensus estimate of $6.58 million. Atara Biotherapeutics has generated ($3.64) earnings per share over the last year (($3.64) diluted earnings per share). Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($3.43) to ($2.67) per share. Atara Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off prior year's report dates.

Atara Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/3/2022
(Estimated)
        
5/5/2022Q1 2022($0.98)($0.87)+$0.11($0.87)$6.58 million$7.31 million    
2/28/2022Q4 2021($0.60)($0.96)($0.36)($0.96)$47.75 million$7.55 million    
11/4/20219/30/2021($0.92)($0.90)+$0.02($0.90)$5.31 million$5.37 million    
8/8/20216/30/2021($0.88)($0.91)($0.03)($0.91)$6.32 million$3.87 million    
5/3/20213/31/2021($0.92)($0.86)+$0.06($0.86)$7.19 million$3.55 million  
2/28/202112/31/2020($0.73)($0.95)($0.22)($0.95)  
11/14/20209/30/2020($1.09)($0.92)+$0.17($0.92)  
8/5/20206/30/2020($1.21)($1.14)+$0.07($1.14)  
5/6/20203/31/2020($1.41)($1.20)+$0.21($1.20)  
2/27/2020Q4 2019($1.34)($1.36)($0.02)($1.36)  
11/7/2019Q3($1.40)($1.31)+$0.09($1.31)  
8/8/2019Q2 2019($1.45)($1.60)($0.15)($1.60)  
5/9/20193/31/2019($1.48)($1.44)+$0.04($1.44)
2/26/2019Q4 2018($1.31)($1.75)($0.44)($1.75)
11/6/20189/30/2018($1.13)($1.29)($0.16)($1.29)
8/1/2018Q2 2018($0.9770)($1.1470)($0.17)($1.15)
5/8/2018Q1 2018($0.9230)($1.0470)($0.1240)($1.05)
2/27/2018Q4 2017($1.15)($1.15)($1.15)
11/9/2017Q3 2017($0.97)($1.02)($0.05)($1.02)
8/7/2017Q2 2017($0.89)($0.94)($0.05)($0.94)
5/4/2017Q1 2017($0.77)($0.88)($0.11)($0.88)
3/9/201712/31/2016($0.98)($0.63)+$0.35($0.63)
11/4/2016Q3 2016($0.79)($0.88)($0.09)($0.88)
8/8/2016Q2($0.61)($0.66)($0.05)($0.66)
5/5/2016Q1($0.55)($0.58)($0.03)($0.58)
3/3/2016Q4 2015($0.48)($0.75)($0.27)($0.75)
11/5/2015Q3 2015($0.53)($0.43)+$0.10($0.43)
8/6/2015Q215($0.42)($0.43)($0.01)($0.24)
5/7/2015Q1 2015($0.36)($0.42)($0.06)($0.42)
2/26/2015Q4 2014($0.35)($0.67)($0.32)($0.67)
11/12/2014Q314($4.20)($4.20)($4.20)












Atara Biotherapeutics Earnings - Frequently Asked Questions

When is Atara Biotherapeutics's earnings date?

Atara Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off last year's report dates. Learn more on ATRA's earnings history.

Did Atara Biotherapeutics beat their earnings estimates last quarter?

In the previous quarter, Atara Biotherapeutics (NASDAQ:ATRA) reported ($0.87) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.98) by $0.11. Learn more on analysts' earnings estimate vs. ATRA's actual earnings.

How can I listen to Atara Biotherapeutics's earnings conference call?

The conference call for Atara Biotherapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Atara Biotherapeutics's conference call transcript?

The conference call transcript for Atara Biotherapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Atara Biotherapeutics generate each year?

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded annual revenue of $20.34 million.

How much profit does Atara Biotherapeutics generate each year?

Atara Biotherapeutics (NASDAQ:ATRA) has a recorded net income of -$340.14 million. ATRA has generated -$3.64 earnings per share over the last four quarters.

What is Atara Biotherapeutics's EPS forecast for next year?

Atara Biotherapeutics's earnings are expected to grow from ($3.43) per share to ($2.67) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ATRA) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.